Tuesday, December 9, 2014
Since CROs began conducting trials for drug sponsors, there has been a lot of quibbling about cost. CROs claim to do the work more quickly, efficiently and inexpensively. But many sponsors have had the opposite experience, saying CROs don’t accomplish recruitment goals and keep extending the trial timelines to do so, adding to the sponsor’s costs. Some claim not all of the data is collected properly, taking months to then clean the data, for which sponsors are charged.
As sponsors and CROs feel the pressure to improve clinical trial efficiency, increase enrollment and maintain a solid bottom line, it’s critical that they avoid information overload while measuring the right performance indicators as data from multiple sources is streamlined.
Durham, N.C.-based Health Decisions, a full-service CRO specializing in high-efficiency adaptive solutions, announced that Argentina-based CRO Klixar has joined its Agile Clinical Network—a newly launched community of research partners formed to eliminate the information gaps and prolonged timelines of complex global studies.
Ecron Acunova, a CRO based out of Germany, India and the United States, appointed Antal Hajos managing director and CEO Europe, replacing ECRON founder and CEO Klaus Wiedey, who will serve as an advisor to the company. In his new role, Hajos will oversee all business, strategic and operational aspects of the European operations. Prior to joining Ecron Acunova last year, Hajos was director of global clinical operations with Altana Pharma and later CEO of Altana/Nycomed’s research and development center and Indian affiliate in Mumbai, India.